These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28756084)

  • 41. The emerging role of carfilzomib combination therapy in the management of multiple myeloma.
    Moreau P
    Expert Rev Hematol; 2014 Apr; 7(2):265-90. PubMed ID: 24521249
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Carfilzomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    Stewart AK
    Future Oncol; 2015; 11(15):2121-36. PubMed ID: 26125319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Emerging therapies for the treatment of relapsed or refractory multiple myeloma.
    Dimopoulos MA; San-Miguel JF; Anderson KC
    Eur J Haematol; 2011 Jan; 86(1):1-15. PubMed ID: 20942854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
    Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
    Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The challenge of cross-trial comparisons using limited data.
    Laubach JP; Faber EA; Voorhees P; Moslehi J; Varga C; Niculescu L; Anderson KC; Richardson PG
    Haematologica; 2014 Aug; 99(8):e145-6. PubMed ID: 25082787
    [No Abstract]   [Full Text] [Related]  

  • 46. Recent trends in the management of newly diagnosed multiple myeloma.
    Reece DE
    Curr Opin Hematol; 2009 Jul; 16(4):306-12. PubMed ID: 19491669
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical characteristics of patients with relapsed multiple myeloma.
    Dimopoulos MA; Terpos E; Niesvizky R; Palumbo A
    Cancer Treat Rev; 2015 Dec; 41(10):827-35. PubMed ID: 26296679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relapsed multiple myeloma.
    Lonial S
    Hematology Am Soc Hematol Educ Program; 2010; 2010():303-9. PubMed ID: 21239810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [I. Proteasome inhibitor for treatment of multiple myeloma].
    Murakami H; Saito T; Handa H
    Gan To Kagaku Ryoho; 2013 May; 40(5):583-8. PubMed ID: 23957065
    [No Abstract]   [Full Text] [Related]  

  • 51. An oral proteasome inhibitor for multiple myeloma.
    Pratt G
    Lancet Oncol; 2014 Dec; 15(13):1417-1418. PubMed ID: 25456357
    [No Abstract]   [Full Text] [Related]  

  • 52. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
    Broyl A; Jongen JL; Sonneveld P
    Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000.
    Siegel DS
    Haematologica; 2014 Aug; 99(8):e147. PubMed ID: 25082788
    [No Abstract]   [Full Text] [Related]  

  • 54. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
    Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Advancement in monoclonal antibody therapy for multiple myeloma.
    Shigle TL; Bashir Q
    Lancet Haematol; 2020 May; 7(5):e354-e355. PubMed ID: 32213343
    [No Abstract]   [Full Text] [Related]  

  • 56. New drugs in multiple myeloma.
    Berenson JR; Yellin O
    Curr Opin Support Palliat Care; 2008 Sep; 2(3):204-10. PubMed ID: 18685422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.
    Suzuki T; Maruyama D; Iida S; Nagai H
    Jpn J Clin Oncol; 2022 Sep; 52(9):966-974. PubMed ID: 35830865
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.
    Spencer A; Walker P; Asvadi P; Campbell DH; Reed K; Herbert BR; Breen EJ; Copeman MC; Dunn RD
    Blood Cancer J; 2019 Jul; 9(8):58. PubMed ID: 31366914
    [No Abstract]   [Full Text] [Related]  

  • 59. Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors.
    Yalnız FF; Akkoç N; Salihoğlu A; Ar MC; Öngören Ş; Eşkazan AE; Soysal T; Aydın Y
    Turk J Haematol; 2017 Aug; 34(3):233-238. PubMed ID: 28270368
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
    Wang Z; Dove P; Wang X; Shamas-Din A; Li Z; Nachman A; Oh YJ; Hurren R; Ruschak A; Climie S; Press B; Griffin C; Undzys E; Aman A; Al-awar R; Kay LE; O'Neill D; Trudel S; Slassi M; Schimmer AD
    Cell Death Dis; 2015 Jul; 6(7):e1815. PubMed ID: 26158521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.